European Patent Office To Grant CRISPR-Cpf1 Patent To Broad Institute, MIT, And Harvard UniversityYahoo FinanceCAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ — The European Patent Office (EPO) has announced it intends to grant its first CRISPR-Cpf1 pate… Continue reading
European Patent Office To Grant CRISPR-Cpf1 Patent To Broad Institute, MIT, And Harvard UniversityPR Newswire (press release)CAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ — The European Patent Office (EPO) has announced it intends to grant its first … Continue reading
European Patent Office To Grant CRISPR-Cpf1 Patent To Broad …PR Newswire (press release)CAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ — The European Patent Office (EPO) has announced it intends to grant its first CRISPR-Cpf1 patent to the …and… Continue reading
Clinical AdvisorStem cell therapy may be effective for multiple sclerosisClinical AdvisorPatients with multiple sclerosis (MS) and treated with autologous hematopoietic stem cell transplantation (AHSCT) have approximately a 50% chance of remaining free… Continue reading
|
Global Market Study on Allergic Rhinitis Treatment: Immunotherapy …
PR Newswire (press release) NEW YORK, Feb. 27, 2017 /PRNewswire/ — ce Market Research in its recent report “Allergic Rhinitis Treatment Market: 2016–2024,” examines the global … |
|
How an oral immunotherapy treatment is combating superbugs — A Q&A with Immuron’s Jerry Kanellos
Becker’s ASC Review Victoria, Australia-based Immuron has developed an oral immunotherapy using polyclonal antibody products, in place of antibiotics, to combat superbugs and antibiotic resistant bacteria, and boost the effectiveness of novel treatments. Immuron’s Chief … |
Oncology Nursing News |
CAR T-Cell Therapy: Nursing’s Key Role in Educating Patients, Caregivers About What to Expect
Oncology Nursing News Interdisciplinary management of refractory non-Hodgkin lymphoma (NHL) patients treated with Kte-C19 (anti-CD19 chimeric antigen receptor [CAR T] cells) in the ZUMA-1 clinical study. Presented at: BMT Tandem Meetings; February 23-26, 2017; Orlando, … |